Press release
Abiomed Announces Q2 FY 2019 Record Revenue of $182 Million, up 37% Over Prior Year
Recent financial and operating highlights include:
- Worldwide Impella® heart pump revenue for the quarter totaled
$175.3 million , an increase of 38% compared to revenue of$127.4 million during the same period of the prior fiscal year.
U.S. Impella heart pump revenue for the quarter totaled$152.2 million , an increase of 34% compared to revenue of$113.6 million during the same period in the prior fiscal year withU.S. patient usage of the Impella heart pumps up 29%.
- Outside the
U.S. , Impella heart pump revenue for the quarter totaled$23.1 million , an increase of 67% compared to revenue of$13.8 million during the same period in the prior fiscal year.
- Gross margin for the second quarter fiscal 2019 was 83.6% compared to 83.7% during the same period in the prior fiscal year.
- Operating income for the second quarter fiscal 2019 was
$50.3 million , or 27.7% operating margin, compared to$31.7 million , or 23.9% operating margin in the prior fiscal year.
- Second quarter fiscal 2019 GAAP net income was
$50.1 million , or$1.09 per diluted share, which benefited from$12.9 million , or$0.28 per diluted share, of excess tax benefits related to employee share-based compensation awards. This compared to GAAP net income of$24.5 million or$0.54 per diluted share for the prior fiscal year, which benefited from$4.5 million , or$0.10 per diluted share, of excess tax benefits.
- The Company’s cash and marketable securities balance as of
September 30, 2018 was$410.4 million . The Company currently has no debt.
- In
September 2018 , a data analysis presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference from Abiomed's Impella® Quality (IQ) Database showed that the utilization of best practices, including early placement of Impella, pre-PCI, led to a 24% relative increase in mean survival for acute myocardial infarction (AMI) cardiogenic shock patients since Impella’s cardiogenic shock FDA post-market approval (PMA) in 2016. The percent of Impella hospitals achieving greater than 70% survival now total 39%, up from 25% prior to the FDA approval.
- Separately at TCT, William O’Neill, MD, medical director of the
Center for Structural Heart Disease atHenry Ford Hospital inDetroit , presented initial data from the first 104 patients treated with the National Cardiogenic Shock Initiative (NCSI) protocol. After more than 20 years of stagnant shock survival rates at roughly 50%, NCSI has now demonstrated a survival of 77%, with 99% of survivors discharged home with their native heart. The NCSI protocol includes placing Impella pre-PCI, reducing the use of inotropes, and right heart hemodynamic monitoring. NCSI is an independent, physician-led collaboration to improve outcomes in cardiogenic shock.
- The Company announces the STEMI DTU FDA safety and feasibility study will be presented in the Late-Breaking Clinical Trials at
10:00 a.m. CST onNovember 11th at theAmerican Heart Association (AHA) Scientific Sessions in Chicago. More information is available at the following link: http://www.abstractsonline.com/pp8/#!/4682/presentation/59042.
- Today, the Company announces that it will host a short investor call to discuss the STEMI DTU FDA safety and feasibility study results on
Monday, November 12 at8:00 a.m. EST .
“We have established a strong foundation with our innovation and technology, balance sheet and intellectual property portfolio,” said
FISCAL YEAR 2019 OUTLOOK
The Company is again increasing the low end of its fiscal year 2019 revenue guidance to
EARNINGS CONFERENCE CALL DETAILS
The Company will host a conference call to discuss the results at
To listen to the call live, please tune into the webcast via http://investor.abiomed.com or dial (855) 212-2361; the international number is (678) 809-1538. A replay of this conference call will be available beginning at
The
ABOUT
Based in
FORWARD-LOOKING STATEMENTS
This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the
For further information please contact:
Director, Investor Relations
978-646-1590
[email protected]
Director, Communications & Public Relations
978-882-8408
[email protected]
| Consolidated Balance Sheets | ||||||||
| (Unaudited) | ||||||||
| (in thousands, except share data) | ||||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 76,382 | $ | 42,975 | ||||
| Short-term marketable securities | 334,064 | 319,274 | ||||||
| Accounts receivable, net | 74,201 | 70,010 | ||||||
| Inventories | 63,656 | 50,204 | ||||||
| Prepaid expenses and other current assets | 13,296 | 11,808 | ||||||
| Total current assets | 561,599 | 494,271 | ||||||
| Long-term marketable securities | - | 37,502 | ||||||
| Property and equipment, net | 134,065 | 117,167 | ||||||
| 33,719 | 35,808 | |||||||
| In-process research and development | 15,730 | 16,705 | ||||||
| Long-term deferred tax assets, net | 116,248 | 70,746 | ||||||
| Other assets | 25,804 | 14,176 | ||||||
| Total assets | $ | 887,165 | $ | 786,375 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 21,884 | $ | 23,565 | ||||
| Accrued expenses | 46,099 | 46,147 | ||||||
| Deferred revenue | 13,996 | 14,970 | ||||||
| Total current liabilities | 81,979 | 84,682 | ||||||
| Other long-term liabilities | 889 | 776 | ||||||
| Contingent consideration | 10,493 | 10,490 | ||||||
| Long-term deferred tax liabilities | 850 | 903 | ||||||
| Total liabilities | 94,211 | 96,851 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders' equity: | ||||||||
| Class B Preferred Stock, |
— | — | ||||||
| Authorized - 1,000,000 shares; Issued and outstanding - none | ||||||||
| Common stock, |
450 | 444 | ||||||
| Authorized - 100,000,000 shares; Issued - 46,935,424 shares at |
||||||||
| Outstanding - 45,038,453 shares at |
||||||||
| Additional paid in capital | 660,132 | 619,905 | ||||||
| Retained earnings | 280,650 | 140,457 | ||||||
| (136,743 | ) | (67,078 | ) | |||||
| Accumulated other comprehensive loss | (11,535 | ) | (4,204 | ) | ||||
| Total stockholders' equity | 792,954 | 689,524 | ||||||
| Total liabilities and stockholders' equity | $ | 887,165 | $ | 786,375 | ||||
| Consolidated Statements of Operations | ||||||||||||||
| (Unaudited) | ||||||||||||||
| (in thousands, except per share data) | ||||||||||||||
| Three Months Ended |
Six Months Ended |
|||||||||||||
| 2018 | 2017 | 2018 | 2017 | |||||||||||
| Revenue | $ | 181,778 | $ | 132,823 | $ | 361,788 | $ | 265,291 | ||||||
| Costs and expenses: | ||||||||||||||
| Cost of product revenue | 29,846 | 21,627 | 60,696 | 43,489 | ||||||||||
| Research and development | 22,717 | 19,390 | 43,990 | 36,321 | ||||||||||
| Selling, general and administrative | 78,895 | 60,080 | 160,034 | 120,677 | ||||||||||
| 131,458 | 101,097 | 264,720 | 200,487 | |||||||||||
| Income from operations | 50,320 | 31,726 | 97,068 | 64,804 | ||||||||||
| Other income: | ||||||||||||||
| Investment income, net | 1,671 | 781 | 3,222 | 1,416 | ||||||||||
| Other (expense) income, net | (158 | ) | (23 | ) | 30 | 56 | ||||||||
| 1,513 | 758 | 3,252 | 1,472 | |||||||||||
| Income before income taxes | 51,833 | 32,484 | 100,320 | 66,276 | ||||||||||
| Income tax provision (benefit) (1) | 1,706 | 7,981 | (39,873 | ) | 4,399 | |||||||||
| Net income | $ | 50,127 | $ | 24,503 | $ | 140,193 | $ | 61,877 | ||||||
| Basic net income per share | $ | 1.11 | $ | 0.56 | $ | 3.13 | $ | 1.41 | ||||||
| Basic weighted average shares outstanding | 44,961 | 44,141 | 44,754 | 44,018 | ||||||||||
| Diluted net income per share (2) | $ | 1.09 | $ | 0.54 | $ | 3.04 | $ | 1.36 | ||||||
| Diluted weighted average shares outstanding | 46,153 | 45,698 | 46,164 | 45,655 | ||||||||||
| (1) Income tax benefit includes the effect of the following item: | ||||||||||||||
| Excess tax benefits related to stock-based compensation awards | $ | 12,928 | $ | 4,434 | $ | 66,765 | $ | 21,276 | ||||||
| (2) Diluted net income per share includes the effect of the following item: | ||||||||||||||
| Excess tax benefits related to stock-based compensation awards | $ | 0.28 | $ | 0.10 | $ | 1.45 | $ | 0.47 | ||||||